Omada Health Reports Third Quarter 2026 Results
- Quarterly Revenue of $91 Million and All-Time High Total Members of 1.1 million
- Revenue Grew 34% and Total Members Increased 36% Year over Year
- Raises Full-Year 2026 Financial Outlook
SAN FRANCISCO - November 5, 2026 - Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2026.
Financial Highlights
- Revenue of $91 million, compared with total revenue of $68 million in Q3 2025
- Gross margin of 76% in the third quarter, up from 66% in Q3 2025
- Non-GAAP gross margin of 78% in the third quarter, up from 68% in Q3 2025
- Net income of $7 million in the third quarter, compared with a net loss of $3 million in Q3 2025
- Adjusted EBITDA of $12 million in the third quarter, compared with Adjusted EBITDA of $2 million in Q3 2025
- Trailing 12-month revenue per Total Member grew approximately 5% year over year to $294
- Cash and cash equivalents of $243 million
Please see the non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release.
Operational Highlights
- Total Members reached 1.1 million, increasing 36% year over year, reflecting continued demand across Omada Health’s integrated cardiometabolic care platform and strong enrollment momentum across diabetes and hypertension programs.
- Average member tenure grew 10% year over year to approximately 2 years and 4 months, which is roughly an additional 2.5 months in program.
“Omada Health delivered its strongest quarter yet, with revenue growing 34% year over year, Total Members increasing 36% and a GAAP gross margin of 76%,” said Sean Duffy, co-founder and CEO of Omada Health. “Our diabetes and hypertension programs led that growth, and average tenure in our programs reached a record of roughly two years and four months. That gives members more time to build lasting habits and the confidence to manage their health. "
Financial Outlook
For the year ending December 31, 2026, Omada Health expects:
- Revenue in the range of $344 million to $346 million, up from prior guidance of $334 million to $340 million, with the midpoint representing approximately 33% growth compared with 2025.
- Adjusted EBITDA in the range of $32 million to $34 million, up from prior guidance of $21 million to $27 million, with the midpoint representing an improvement of approximately $27 million, or roughly five and a half times, compared with 2025.
We have not provided an outlook for net income (loss) (GAAP) or a reconciliation of expected Adjusted EBITDA to net income (loss) (GAAP) because net income (loss) (GAAP) on a forward-looking basis is not available without unreasonable effort due to the potential variability and complexity of the items that are excluded from Adjusted EBITDA, such as loss on debt extinguishment; provision for income taxes; depreciation and amortization; share-based compensation; change in fair value of warrant liabilities; amortization of intangible assets; and loss on disposal of property and equipment.
Conference Call
Omada Health will host a conference call at 1:30 p.m. PT/4:30 p.m. ET today, November 5, 2026, during which management will discuss third quarter 2026 results.
A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months.
Those participating via conference call can preregister using the following link: https://register-conf.media-server.com/register/BIcb6fa0e5bd8d4b91a30bc5b4de7e5fb8